STOCK TITAN

Spero Therapeutics Q3 2026 loss widens to $44.3M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Spero Therapeutics reported a third-quarter 2026 net loss of $44.3 million, compared with a $7.4 million net loss in third-quarter 2025; diluted net loss per share was $0.76 versus $0.13. There was no revenue, compared with $5.4 million a year earlier. Research and development expenses were $38.2 million versus $8.6 million, primarily due to the $35 million upfront payment for the SP001 license. Cash and cash equivalents were $107.9 million as of September 30, 2026, and Spero expects the cash to fund operating expenses and capital expenditures into the second half of 2029.

In July 2026, Spero licensed exclusive worldwide rights to SP001, excluding Greater China, and closed a $105 million non-recourse, non-dilutive milestone and royalty financing with affiliates of HealthCare Royalty Partners in exchange for a portion of anticipated Utebzi payments owed by GSK. Spero plans to initiate a Phase 2 study of SP001 in IgG4-related disease in Q2 2027. SP001 is an anti-CD40L antibody; Spero also appointed Debra Jeske Zack, M.D., Ph.D., as chief medical officer.

1 point · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.Cash is expected to fund operations and capital expenditures into the second half of 2029.

Negative

  • Major pointNet loss: $44.3 million in Q3 2026, versus $7.4 million in Q3 2025.
  • Moderate pointRevenue: no third-quarter 2026 revenue, versus $5.4 million a year earlier.

Filing Explained

The completed July financing exchanged part of anticipated GSK Utebzi payments for $105 million; after required note payments to HCRx are satisfied, Spero retains a 35% interest in any remaining GSK payments.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash and cash equivalents $107.9 million As of September 30, 2026; expected to fund operating expenses and capital expenditures into the second half of 2029.
Research and development expenses $38.2 million Third quarter 2026; compared with $8.6 million in third-quarter 2025.
SP001 upfront payment $35 million Paid to Innovent upon closing of the licensing agreement during the quarter.
Net loss $44.3 million Third quarter 2026; compared with a $7.4 million net loss in third-quarter 2025.
Diluted net loss per share of common stock $0.76 Third quarter 2026; compared with $0.13 in third-quarter 2025.
Revenue No revenue Third quarter 2026; compared with $5.4 million in third-quarter 2025.
General and administrative expenses $3.7 million Third quarter 2026; compared with $4.2 million in third-quarter 2025.
Milestone and royalty financing $105 million Closed in July 2026 with affiliates of HealthCare Royalty Partners.
Fc-silent technical
"fully humanized, Fc-silent IgG1 monoclonal antibody"
monoclonal antibody medical
"third-generation, fully humanized, Fc-silent IgG1 monoclonal antibody"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
CD40L medical
"monoclonal antibody targeting CD40L"
CD40L (CD40 ligand) is a protein found on the surface of certain immune cells that acts like a molecular switch, helping immune cells talk to one another and coordinate responses. Investors should care because drugs that block or mimic this switch are common targets in biotech — they can treat autoimmune diseases, prevent transplant rejection, or boost vaccines — and clinical trial results or safety issues around CD40L-targeting therapies can strongly affect a company’s value.
non-recourse, non-dilutive milestone and royalty financing financial
"$105 million non-recourse, non-dilutive milestone and royalty financing"
FcRn interaction technical
"including FcRn interaction that supports IgG-like half-life"
Research and development expenses $38.2 million Compared with $8.6 million in third-quarter 2025.
Net loss $44.3 million Compared with a $7.4 million net loss in third-quarter 2025.
Diluted net loss per share of common stock $0.76 Compared with $0.13 in third-quarter 2025.
Revenue No revenue Compared with $5.4 million in third-quarter 2025.
General and administrative expenses $3.7 million Compared with $4.2 million in third-quarter 2025.
Guidance

Spero expects cash and cash equivalents to fund operating expenses and capital expenditures into the second half of 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were SPRO's third-quarter 2026 financial results?

Spero reported a $44.3 million net loss, or $0.76 diluted net loss per share, compared with a $7.4 million net loss, or $0.13 per share, in third-quarter 2025. There was no revenue in third-quarter 2026, compared with $5.4 million a year earlier.

How long does SPRO expect its cash to last?

As of September 30, 2026, Spero had $107.9 million in cash and cash equivalents, which it expects to fund operating expenses and capital expenditures into the second half of 2029.

How does SPRO's $105 million financing affect its Utebzi payments?

Spero closed the $105 million non-recourse, non-dilutive milestone and royalty financing in exchange for a portion of anticipated Utebzi payments owed by GSK. Spero retains a 35% interest in GSK payments remaining after required note payments to affiliates of HealthCare Royalty Partners are satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001701108false00017011082026-11-122026-11-12

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

 

SPERO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-38266

46-4590683

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

 

 

 

675 Massachusetts Avenue, 14th Floor

Cambridge, Massachusetts

02139

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code (857) 242-1600

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.001 par value

 

SPRO

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


 

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2026, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing its results for the third quarter ended September 30, 2026. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, or incorporated by reference in any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 


 

Item 9.01 Financial Statements and Exhibits

(d)
Exhibits

 

Exhibit

No.

 

Description

99.1

 

Press release issued by Spero Therapeutics, Inc. on November 12, 2026

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)

 

 


 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 12, 2026

SPERO THERAPEUTICS, INC.

 

 

 

 

 

By:

/s/ Esther Rajavelu

 

 

Esther Rajavelu

 

 

Chief Executive Officer and Chief Financial Officer

 

 


 

Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update

 

•
SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD)
•
Cash and cash equivalents of $107.9 million as of September 30, 2026, expected to fund operations into the second half of 2029

 

CAMBRIDGE, Mass., November 12, 2026 – Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for immune-mediated diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

 

“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy,” said Esther Rajavelu, President and Chief Executive Officer of Spero. “Our focus is now firmly on execution as we advance SP001 toward a Phase 2 study in IgG4-related disease, while continuing to evaluate additional indications where CD40L inhibition may benefit patients.”

 

Recent Business Highlights

SP001 In-Licensed from Innovent Biologics

•
In July 2026, Spero in-licensed SP001 from affiliates of Innovent Biologics, Inc., obtaining exclusive worldwide rights, excluding Greater China (Mainland China, Hong Kong, Macau, and Taiwan), to research, develop, manufacture, and commercialize the antibody.
•
SP001 is a third-generation, fully humanized, Fc-silent IgG1 monoclonal antibody targeting CD40L. Innovent completed Phase 1 single and multiple ascending dose studies in healthy volunteers and a Phase 1b multiple ascending dose study in patients with primary Sjögren’s disease in China. Phase 1b results were presented at the EULAR 2026 Congress.
•
Spero plans to initiate a Phase 2 study for SP001 in IgG4-RD in Q2 2027. IgG4-RD is a serious, rare, chronic fibroinflammatory disease with significant treatment burden and limited therapeutic options.

 

$105 Million Non-Recourse, Non-Dilutive Milestone and Royalty Financing

•
In July 2026, Spero closed a $105 million non-recourse, non-dilutive milestone and royalty financing with affiliates of HealthCare Royalty Partners, a business of KKR (HCRx), in exchange for a portion of anticipated Utebzi payments owed by GSK to Spero. Spero retains a 35% interest in any GSK payments remaining after the required note payments to HCRx are satisfied, preserving potential long-term upside from Utebzi.

 

Corporate

•
In July 2026, the Company appointed Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer to lead its clinical development strategy and organization. Dr. Zack most recently served as Chief Medical Officer of Exagen Inc., following clinical leadership roles at Xencor Inc., Novartis and Amgen.
•
Spero recently appointed Amy Rock, Ph.D. as Chief Regulatory and Quality Officer to lead the Company’s global regulatory strategy, quality and pharmacovigilance functions, including engagement with global health authorities to support the clinical development of SP001 in IgG4-related disease and potential additional indications.
•
Spero appointed William Ho, M.D., Ph.D. to its Board of Directors and Development Committee, effective November 10, 2026. Dr. Ho brings more than twenty years of clinical development experience across oncology, allergy and immunology, including extensive experience in the translational and clinical development of novel therapeutics.
•
Concurrent with Dr. Ho’s appointment, Dr. Patrick Vink stepped down from Spero’s Board following eleven years of service, during which he helped guide the Company from its IPO through its evolution into an established public company and its current strategic focus on immune-mediated diseases.

 

 


 

Third Quarter 2026 Financial Results

•
Research and development expenses for the third quarter of 2026 were $38.2 million, compared to $8.6 million for the same period in 2025. The increase was primarily due to the $35M upfront payment made to Innovent upon the closing of the licensing agreement during the quarter.
•
Spero reported a net loss of $44.3 million for the third quarter of 2026 compared to a net loss of $7.4 million for the third quarter of 2025, or a diluted net loss per share of common stock of $0.76 and $0.13, respectively.
•
There was no revenue for the third quarter of 2026, compared to total revenue of $5.4 million for the third quarter of 2025.
•
General and administrative expenses for the third quarter of 2026 were $3.7 million, compared to $4.2 million for the same period in 2025. The decrease was primarily due to decreased personnel costs.
•
As of September 30, 2026, cash and cash equivalents were $107.9 million, reflecting receipt of proceeds from the royalty financing completed in July 2026. Spero expects its cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures into the second half of 2029.

For further details on Spero’s financials, refer to Spero’s Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (SEC) today.

 

About IgG4-Related Disease

IgG4-related disease (IgG4-RD) is a rare, chronic, immune-mediated condition characterized by inflammation and fibrosis that can affect multiple organs, including the pancreas, kidneys, lungs, salivary and lacrimal glands, and lymph nodes. The pathogenesis of IgG4-RD is complex and is believed to involve dysregulation across multiple components of the immune system, including B cells, T cells and innate immune cells, including antigen-presenting cells, which interact to drive the inflammatory and fibrotic processes underlying the disease. The disease can cause progressive and potentially irreversible organ damage if not adequately controlled. These challenges underscore the need for additional targeted therapies that can provide durable disease control while reducing reliance on chronic immunosuppression.

 

About SP001

SP001 is a third-generation, fully humanized, Fc-silent IgG1 monoclonal antibody targeting CD40L, an upstream immune activation signal involved in T-cell, B-cell, antigen-presenting cell, and platelet biology. By blocking CD40L, SP001 has the potential to provide a targeted non-B-cell-depleting treatment across multiple immune-mediated diseases where immune-cell interactions drive chronic inflammation, relapse, and tissue damage. SP001 is designed to address platelet activation concerns associated with earlier anti-CD40L antibodies, while preserving key monoclonal antibody properties, including FcRn interaction that supports IgG-like half-life.

 

About Spero Therapeutics

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immune-mediated diseases. For more information, visit www.sperotx.com

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, statements relating to Spero's plans to advance SP001 into a Phase 2 study in IgG4-related disease in Q2 2027; Spero's plans to explore the use of SP001, and the role of CD40L inhibition, in additional indications that may benefit patients; Spero's expectation that anticipated cash runway, and future milestones. Forward-looking statements are based on Spero's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to the completion and integration of the Innovent transaction; Spero's ability to successfully develop SP001; the timing and outcome of clinical trials and regulatory interactions; the ability to obtain and maintain regulatory approvals; potential safety, efficacy, manufacturing, supply, intellectual property, financing, competitive, and market risks; and other risks described in Spero's filings with the Securities and Exchange Commission. Spero undertakes no obligation to update any forward-looking statements, except as required by law.

 

 

 


 

Investor Relations Contact:
Shai Biran, Ph.D.
Spero Therapeutics
IR@Sperotx.com
 

Media Inquiries:

media@sperotx.com

 


 

img92614603_0.jpg

 

img92614603_1.jpg

 

 


Filing Exhibits & Attachments

2 documents

Keep reading